Images
- The Spanish Association for Cancer Research (ASEICA) has recognized the ICREA researcher at IRB Barcelona for her career in cancer genomics and her contribution to giving visibility to women in oncology research.
- The awards ceremony will take place during the 21st ASEICA International Congress in Seville from 25 to 27 November.
Dr. Núria López-Bigas, ICREA Research Professor at IRB Barcelona, has been awarded the 2026 ASEICA Women Award (Premio ASEICA Mujer 2026). With this distinction, the Spanish Association for Cancer Research (ASEICA) recognizes both her scientific career and contributions to cancer genomics, as well as her role as a female role model in oncology research.
Dr. López-Bigas leads the Biomedical Genomics laboratory, which combines biology and bioinformatics to study the genetic mechanisms involved in cancer development. Her research has helped advance the identification of genes and mutations responsible for tumour development and the understanding of the processes that drive the accumulation of genetic alterations in cells.
An international reference in cancer genomics, Dr. López-Bigas has been a member of the European Molecular Biology Organization (EMBO) since 2016 and of the Royal Spanish Academy of Sciences since 2024, and in 2022 she received the ISCB Innovator Award. She currently leads the European project CGI-Clinics, which aims to improve the interpretation of tumour genomes to support clinical decision-making, and co-leads PROMINENT, an international initiative funded by Cancer Grand Challenges to investigate the mechanisms driving cancer development and evolution.
“Núria López-Bigas is one of the leading figures in oncology research in our country. Her contributions to cancer genomics have been fundamental to better understanding the mechanisms that drive tumor development and advancing toward more precise oncology. With this award, we want to recognize not only her scientific excellence and international projection, but also her role in giving visibility to women in oncology research. Careers like hers are essential to continue moving toward science with equal opportunities,” highlighted Rafael López, President of ASEICA.
In the same edition of the awards, ASEICA also presented the ASEICA Young Investigator Award in Basic Research to Dr. Francisco Martínez-Jiménez—a former member of Dr. López-Bigas’s laboratory who now leads the Computational Immunogenomics Lab at the Vall d'Hebron Institute of Oncology (VHIO)—for his work on tumor evolution, metastasis, and response to immunotherapy.
In addition to Dr. López-Bigas and Dr. Martínez-Jiménez, ASEICA also recognized Dr. Andrés Cervantes (Scientific Director of INCLIVA and Head of the Medical Oncology Department at Hospital Clínico Universitario de Valencia) with the 2026 ASEICA Cancer Research Award, Dr. Rodrigo Sánchez-Bayona (medical oncologist at Hospital Universitario 12 de Octubre in Madrid) with the Young Investigator Award in Clinical Research, and the Spanish Association of Metastatic Breast Cancer (AECMM) with the Social Commitment Award.
The awards ceremony will take place during the 21st ASEICA International Congress, which will be held in Seville from 25 to 27 November.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).